Researcher

Yuan Liu

University of Miami

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · PREPRINT

Federated Prompt Learning: A Unified Framework, Empirical Analysis, and Future Directions

arXiv

A survey paper that frames research questions and reviews existing methods without presenting new empirical results, original data, or comparative evidence from the authors' own work.

Hypothesis-GeneratingChen Qiu Hongyuan Zhang Zhihong Tian

AUG 13, 2026 · JOURNAL ARTICLE

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study

Frontiers in Oncology

Single-center retrospective study showing superior PFS and ORR for ICI+chemotherapy versus bevacizumab+chemotherapy in driver gene-negative NSCLC, but limited by retrospective design, unbalanced group sizes, and lack of adjustment for confounders.

PromisingJing Fei Lung Cancer Treatments and Mutations Yinzhen Li

Reported

Median PFS (ICIs+chemotherapy)14.330 months

Median PFS (bevacizumab+chemother…9.60 months

PFS p-value0.014

AUG 7, 2026 · JOURNAL ARTICLE

Intercellular mitochondrial exchange shapes tumor evolution, microenvironment adaptation, and therapeutic vulnerabilities

Translational Oncology

A narrative review synthesizing mechanistic evidence on mitochondrial transfer in tumors; raises questions about therapeutic vulnerabilities but does not report original empirical results or clinical outcomes.

Hypothesis-GeneratingTianyu Wang Aiqin Chang Zhiyong Wu

Study details

DesignNarrative review